The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world adoption of 3 months of adjuvant oxaliplatin chemotherapy in patients with stage III colorectal cancer (CRC).
 
Tharani Krishnan
No Relationships to Disclose
 
Joao Paulo Solar Vasconcelos
No Relationships to Disclose
 
Howard J Lim
Honoraria - Amgen; Astellas Pharma; AstraZeneca Canada; BMS Canada; Dicephera Pharmaceuticals, Inc.; eisai; Ipsen; Merck; Roche Canada; Taiho Pharmaceutical; Varian Medical Systems
Research Funding - Roche (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Eisai; Taiho Oncology
 
Jonathan M. Loree
Consulting or Advisory Role - Advanced Accelerator Applications; AMGEN; Bayer; Ipsen; Pfizer; Taiho Pharmaceutical
Research Funding - Amgen (Inst); Ipsen (Inst)
 
Janine Marie Davies
Honoraria - AstraZeneca; Eisai; Taiho Pharmaceutical
Consulting or Advisory Role - Apotex; Eisai; Incyte
 
Karamjit Gill
No Relationships to Disclose
 
Sharlene Gill
Honoraria - Amgen; Eisai
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb Canada; Eisai; Ipsen; Merck; Pfizer; Roche Canada
Research Funding - Incyte (Inst)